Status:
COMPLETED
Relationship Between Serum β2-Microglobulin and Infiltration of CD8+ in the Tumor Tissue of Hodgkin's Lymphoma Patients
Lead Sponsor:
Tishreen University
Conditions:
Hodgkin Lymphoma
Eligibility:
All Genders
Brief Summary
In newly diagnosed Hodgkin lymphoma patients, pre-treatment Beta-2 Microglobulin (B2M) levels will be measured. A thorough baseline assessment will be performed using CT imaging, and tumor tissue samp...
Eligibility Criteria
Inclusion
- Newly diagnosed patients with Hodgkin lymphoma
- No prior history of malignancy
- Absence of primary or secondary immunodeficiencies
Exclusion
- Patients who have previously undergone treatment
- Patients with acute or chronic infections
- Patients with renal disorders
- Individuals with autoimmune diseases
- HIV-positive patients
Key Trial Info
Start Date :
January 4 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 15 2024
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT06564259
Start Date
January 4 2024
End Date
August 15 2024
Last Update
August 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tishreen University
Latakia, Syria